As scientists train the immune system to fight cancer, others look to combat costs

June 2, 2017 by Ian Haydon, The Conversation

Poison, radiation or surgery. For decades now, these have been the only weapons available in the war against cancer. But everyone who has known cancer up close – patients, their loved ones and physicians – has longed for a better way.

Immunotherapy is emerging as the so-called fourth pillar of therapy, alongside chemotherapy, radiation and surgery. Unlike these older approaches, immunotherapy works with your body by boosting your immune system's natural ability to detect and eliminate cancer.

"Boosting your immune system" might sound cheap, but with a foe like cancer, simply upping your vitamin C intake won't cut it.

Billions of research dollars, including from the Obama administration's Cancer Moonshot Initiative, are being poured into finding new, molecular tools to enhance the immune system's ability to fight cancer of all types. Now that these new therapies are starting to work, some researchers are turning their attention to something else: driving down costs.

Engineering antibodies to better recognize cancer

Antibodies are a natural part of the immune system. Their job is to physically adhere to specific molecules, including to proteins found on the surface of cells. If antibodies are able to stick to their target, they can (in some cases) recruit other parts of the immune system to take it out.

Perhaps the most famous anti-cancer antibody drug available today is trastuzumab, or Herceptin. In certain forms of breast cancer, a growth-related protein called HER2 is extra abundant on the surface of . Herceptin is engineered to bind to HER2, which not only slows down tumor growth, but also allows the rest of the immune system to mount an attack.

Cancer cells displaying an Achilles’ heel - the HER2 biomarker (red dots). Credit: Journal of Pathology Informatics CC-NC-SA

Herceptin has proven effective against HER2-positive breast cancers in some , although, as with other antibody-based cancer therapies, it is not cheap and not without the risk of side effects.

Taking the brakes off T cells

We now know that can be destroyed by a specialized type of white blood cell called a killer T cell.

To avoid being attacked by the immune system, are decorated with molecules that turn killer T cells off whenever they come near. As normal cells transition into a cancerous state, some pick up the ability to coat themselves in these so-called "checkpoint" molecules, allowing them to put the brakes on even a robust immune system attack. This process is known as immunoediting. It is now considered a hallmark of many of the most hazardous types of cancer.

One such checkpoint molecule is PD-L1, a protein that shuts down killer T cells by flipping a switch on the T cell itself. When cancer picks up the ability to make more PD-L1, it becomes more effective at shutting down T cells.

Designer antibodies that disrupt this process are already available in the U.S. for patients with inoperable metastatic melanoma, certain non-small-cell lung cancers, renal cell carcinoma and classic Hodgkin's lymphoma.

Nivolumab is one such proven drug but, like many engineered antibodies, it comes at a steep price. How steep?

"Approximately 4,000 times the cost of gold," according to oncologist Dr. Leonard Saltz, chief of gastrointestinal oncology at Memorial Sloan Kettering Cancer Center in New York City. Speaking on value at a 2015 meeting of the American Society of Clinical Oncology, Saltz warned, "As a clinician, I want these drugs and others like them to be available for my patients. As one who worries about how we will make them available and minimize disparities, I have a major problem, and that is that these drugs cost too much."

A delicate molecular balance allows the immune system to tell friend from foe – cancer exploits this. Credit: Genentech

Protein engineer Cassie Bryan at the University of Washington's Institute for Protein Design is working to come up with a new, more affordable way of disrupting cancer's ability to disable T cells at the molecular level.

In collaboration with oncologists from Seattle Children's Hospital and the Fred Hutchinson Cancer Research Center in Seattle, Bryan has produced a tiny, non-antibody protein which sticks to T cells in a way that should keep PD-L1 from deactivating them. This new class of computer-generated checkpoint inhibitor should be easier to produce than an engineered antibody due to its small size and will be tested for T cell boosting activity soon.

Genetically enhanced T cells

The most advanced frontier in cancer immunotherapy is a type of precision medicine known as adoptive cell therapy. It consists of isolating T cells from the blood of individual patients, enhancing their cancer-killing activity in the lab, and then reinfusing the turbocharged T cells back into the same patient. Isolated T cells can be enhanced by treating them with a drug directly or by genetic engineering.

A single infusion of enhanced T cells can produce astonishing results in some patients, including complete remission of otherwise untreatable disease.

Initial results from an ongoing adoptive cell therapy trial being conducted by Stanley Riddell, a pioneer in this field, and colleagues revealed that more than 90 percent (27 of 29) of enrolled patients with advanced acute lymphoblastic leukemia achieved remission, as well as 63 percent (19 of 30) of patients with non-Hodgkin's lymphoma.

Following a single half-hour infusion of reengineered T cells, one patient remarked that his tumors were "melting like ice cubes."

Riddell called the results "simply astounding."

Protein engineer Cassie Bryan is designing more affordable cancer immunotherapies. Credit: Ian Haydon / UW Institute for Protein Design

We are still in the early days of adoptive cell therapy. For now, blood cancers are proving more susceptible to attack than difficult-to-penetrate solid tumors. And because this treatment involves engineering an individual patient's T cell in a lab, cost and broad availability are a concern.

A more general approach?

Several research teams and private ventures are working to develop more general T cell therapies, either by enhancing and storing generic T cells that could be infused into multiple patients or by building nanotechnology that moves the laboratory into the patient.

To help accomplish the latter, a team of researchers here in Seattle has designed injectable nanoparticles which carry the DNA needed to reprogram T cells to better fight cancer. Mice that received their nanoparticle therapy showed the same rate of leukemia regression as mice that received the more conventional infusion of lab-optimized T-cells.

None of these experimental therapies is without risk. Taking the brakes off T cells allows the immune system to attack cancer, but if T cells get out of control, other healthy cells may be harmed. Anticipating this, researchers have begun installing "suicide genes" into engineered T .

Immunotherapy represents the cutting edge of both oncology and biotechnology. Our understanding of the fundamental biology and our tools for manipulating it are linked, and together are producing some of the most promising cancer breakthroughs in history.

Explore further: Triple immunotherapy for rare skin cancer shows promise in small, early-stage trial

Related Stories

Triple immunotherapy for rare skin cancer shows promise in small, early-stage trial

May 30, 2017
Three out of four patients treated with an experimental combination of three different therapies for the rare skin cancer known as Merkel cell carcinoma are in complete remission following the treatment, according to study ...

Cancer immunotherapy may work in unexpected way

May 18, 2017
Antibodies to the proteins PD-1 and PD-L1 have been shown to fight cancer by unleashing the body's T cells, a type of immune cell. Now, researchers at the Stanford University School of Medicine have shown that the therapy ...

Rush clinical trial provides new kidney cancer immunotherapy option

May 19, 2017
Rush University Medical Center is among the first hospitals in the nation, and the only one in Illinois, to provide patients fighting advanced kidney access to a new combination immunotherapy that targets different immune ...

Identifying a novel target for cancer immunotherapy

April 12, 2017
Targeting a molecule called B7-H4—which blocks T-cells from destroying tumor cells—could lead to the development of new therapies that boost the immune system's ability to fight cancer, according to a review published ...

Crafting a better T cell for immunotherapy

February 22, 2016
T-cell therapy, a form of immunotherapy that uses a patient's own immune cells to attack their cancer, has been making waves recently. The "living" therapy involves engineering the patient's T cells in the laboratory to carry ...

Novel 'barcode' tracking of T cells in immunotherapy patients identifies likely cancer

February 24, 2017
A new discovery by researchers at the Fred Hutchinson Cancer Research Center in Seattle makes an important step in identifying which specific T cells within the diverse army of a person's immune system are best suited to ...

Recommended for you

Targeting molecules called miR-200s and ADAR2 could prevent tumor metastasis in patients with colorectal cancer

April 24, 2018
Colorectal cancer is the third most common cancer worldwide and the third-leading cause of cancer-related deaths. The main cause of death in patients with colorectal cancer is liver metastasis, with nearly 70% of patients ...

Changes in breast tissue increase cancer risk for older women

April 24, 2018
Researchers in Norway, Switzerland, and the United States have identified age-related differences in breast tissue that contribute to older women's increased risk of developing breast cancer. The findings, published April ...

Removing the enablers: Reducing number of tumor-supporting cells to fight neuroblastoma

April 24, 2018
Investigators at the Children's Center for Cancer and Blood Diseases at Children's Hospital Los Angeles provide preclinical evidence that the presence of tumor-associated macrophages—a type of immune cell—can negatively ...

Technology used to map Mars now measuring effect of treatment on tumours

April 24, 2018
A machine learning approach for assessing images of the craters and dunes of Mars, which was developed at The University of Manchester, has now been adapted to help scientists measure the effects of treatments on tumours.

New test could tell doctors whether patients will respond to chemotherapy

April 24, 2018
Less than half the patients diagnosed with cancer respond favorably to chemotherapy, but a new method for testing how patients will respond to various drugs could pave the way for more personalized treatment.

Vitamin A derivative selectively kills liver cancer stem cells

April 23, 2018
Acyclic retinoid, an artificial compound derived from vitamin A, has been found to prevent the recurrence of hepatocellular carcinoma (HCC), the most common form of liver cancer. Now, in research published in Proceedings ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.